

Evaluation Report for Category B, Subcategory 5.0 Application

Application Number:	2023-0165	
Application:	New Maximum Residue Limits for a Previously Assessed	
	Technical Grade Active Ingredient	
Product:	Rynaxypyr Technical Insecticide	
Registration Number:	28979	
Active ingredient (a.i.):	Chlorantraniliprole	
PMRA Document Number : 3606972		

Purpose of Application

The purpose of this application was to establish maximum residue limits (MRLs) for residues of chlorantraniliprole in/on a variety of imported crops.

Health Assessments

Residue data from field trials conducted in the United States, Japan, and Malaysia were submitted to support the MRLs on avocado, tea, and palm fruit. Previously reviewed residue data from field trials conducted in/on tea were also reassessed in the framework of this application.

Chlorantraniliprole was applied to avocado, green tea, and palm fruit at equivalent and exaggerated rates, and harvested according to label directions. In addition, a processing study in treated green tea and palm fruit was reviewed to determine the potential for concentration of residues of chlorantraniliprole into processed commodities.

Maximum Residue Limits

The recommendation for proposed MRLs for chlorantraniliprole was based upon the submitted field trial data, and the guidance provided in the <u>OECD MRL Calculator</u>. Maximum residue limits to cover residues of chlorantraniliprole in/on crops and processed commodities are proposed as shown in Table 1. Residues in processed commodities not listed in Table 1 are covered under the proposed MRLs for the raw agricultural commodities (RACs).

TABLE 1.Summary of Field Trial and Processing Data Used to Support Maximum ResidueLimits (MRLs)							
	Application		Residues (ppm)			Currently	
Commodity	Method/ Total Application Rate (g a.i./ha)	PHI (days)	LAFT	HAFT	Experimental Processing Factor	Established MRL (ppm)	Proposed MRL (ppm)
Avocado	Foliar / 223- 226	1-7	0.043	0.155	n/a	None	0.3
Palm fruit	Foliar / 61-62	1-19	0.180 (Min)	0.380 (Max)	2.5x (palm oil)	None	0.8 (palm fruit) 2 (palm oil)



TABLE 1. Summary of Field Trial and Processing Data Used to Support Maximum Residue Limits (MRLs)							
Commodity	Application	PHI	Residues	(ppm)	Experimental	Currently	Proposed MRL
Tea (dried leaves)	Foliar / 150- 206	3	18.90	31.60	n/a	None	80

g a.i./ha = grams of active ingredient per hectare; ppm = parts per million; LAFT = Lowest Average Field Trial; HAFT = Highest Average Field Trial

Following the review of all available data, the MRLs proposed in Table 1 are recommended to cover residues of chlorantraniliprole. Dietary risks from exposure to residues of chlorantraniliprole in these crop commodities at the proposed MRLs were shown to be acceptable for the general population and all subpopulations, including infants, children, adults and seniors. Thus, the foods that contain residues as listed in Table 1 are considered safe to eat.

Toxicology and occupational exposure assessments were not required for this application.

Chemistry, Environmental and Value Assessments

Chemistry, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to establish MRLs for residues of chlorantraniliprole in/on avocado, tea, and palm fruit.

References

PMRA Document	
Number	Reference
3471681	2017, Determination of residues of chlorantraniliprole after two applications of Altacor 35 WG in oil palm trees at 4 sites in Malaysia in 2015, DACO: 7.4.1,7.4.5.
3426297	2021, Crop field trial on Japanese Green Tea with SAMCOR Flowable 10, DACO: 7.2,7.2.1,7.2.2, 7.2.3A,7.3,7.4,7.4.1,7.4.2.
3426298	2021, Crop field trial on Japanese Green Tea with SAMCOR Flowable 10, DACO: 7.2,7.2.1,7.2.2, 7.2.3A,7.3,7.4,7.4.1,7.4.2.
3426295	2021, Magnitude and Decline of Chlorantraniliprole (E2Y45) Residues in Avocados following two Foliar applications of Chlorantraniliprole 35WG, DACO: 7.2,7.2.1,7.2.2, 7.2.3A,7.3,7.4,7.4.1,7.4.2.

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written

permission of Health Canada, Ottawa, Ontario K1A 0K9.